Lupin Limited on July 01, 2026 disclosed that its wholly owned subsidiary Nanomi B.V. incorporated in the Netherlands, has completed the acquisition of 11,794,497 shares from certain existing shareholders of Multicare Pharmaceuticals Philippines, Inc. (MPPI). The acquisition closed on July 01, 2026, following definitive agreements signed earlier in the year, as referenced in the company's intimations dated April 01, 2026 and May 29, 2026. MPPI is a subsidiary of Nanomi B.V.
Prior to this transaction, Nanomi B.V. held 56.28% of the issued share capital of MPPI. Post completion of the acquisition, Nanomi B.V.'s shareholding in the Philippine subsidiary has increased to 99.89% effective July 01, 2026. The transaction involved the purchase of shares from multiple existing shareholders of MPPI.
MPPI also completed a buy-back of 61,118 shares from two existing shareholders on July 01, 2026. The buy-back process for the balance 30,559 shares is currently in progress. These buy-back transactions were previously disclosed by Lupin in an intimation dated March 30, 2026.
The combined effect of the acquisition and buyback transactions resulted in Nanomi B.V.'s consolidated stake in MPPI rising from 56.28% to 99.89%. The transactions bring MPPI substantially under the direct control of Nanomi B.V. and by extension, under the Lupin group.
Lupin made these disclosures to the National Stock Exchange of India Limited (NSE) and BSE Limited under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was signed by Amit Kumar Gupta, Company Secretary and Compliance Officer of Lupin Limited.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.